Valeant Pharmaceuticals Announces All-Cash Offer to Acquire Afexa Life Sciences for C$76M

Valeant Pharmaceuticals International VRX, announced today that it has agreed to acquire Afexa Life Sciences Inc. for approximately C$76 million. Afexa, a health-science company headquartered in Edmonton, Alberta, Canada, currently markets several consumer brands, such as COLD-FX® and COLDSORE-FX™, and has annual revenues of approximately C$40 million.